The Food and Drug Administration granted expedited approval to daraxonrasib, marking a significant development in pancreatic cancer treatment. The drug, marketed as Rasonque by Revolution Medicines, represents a novel approach to targeting the disease and will be available to U.S. patients as a daily oral medication.
In a randomized clinical trial involving 500 patients with metastatic pancreatic cancer that had become resistant to prior treatments, those receiving daraxonrasib achieved a median survival of 13.2 months compared with 6.7 months for patients treated with chemotherapy. The adverse effects reported included skin rash, mouth sores, diarrhea, and other digestive complications. Regulatory officials completed their review more than six months ahead of their scheduled target date.
The drug’s mechanism of action involves targeting mutations in the RAS gene family, particularly KRAS mutations that play a central role in pancreatic cancer development. These mutations had previously been considered difficult to address pharmacologically due to structural challenges in drug binding. Daraxonrasib employs a molecular binding technique to attach to multiple KRAS subtypes, effectively blocking the mutated proteins that fuel tumor growth in more than 90% of pancreatic cancer cases.
Pancreatic cancer remains among the most lethal malignancies, with an estimated 67,000 new diagnoses and more than 52,000 deaths expected in the United States this year. The five-year overall survival rate stands at 13%. The disease’s deadliness is largely attributable to detection difficulties, as symptoms often remain undetected until the cancer has spread to other organs.
Revolution Medicines set the monthly supply cost at approximately $39,800. The company is investigating applications of its technology in other cancer types, including lung cancer. Industry observers anticipate the approval may stimulate development of additional therapeutic options targeting similar mechanisms in various malignancies.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI